Compare IAF & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IAF | RCEL |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | 226 |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.2M | 132.0M |
| IPO Year | N/A | N/A |
| Metric | IAF | RCEL |
|---|---|---|
| Price | $12.30 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 54.8K | ★ 171.8K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $49.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.73 | $3.22 |
| 52 Week High | $14.54 | $10.28 |
| Indicator | IAF | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 46.60 |
| Support Level | $12.72 | $3.36 |
| Resistance Level | $13.19 | $4.09 |
| Average True Range (ATR) | 0.23 | 0.22 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 98.58 | 63.89 |
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.